HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries

Elena Nicod, Lieven Annemans, Anna Bucsics, Anne Lee, Sheela Upadhyaya, Karen Facey
2017 Health Policy  
Acknowledgements: This paper was inspired by questions from Scott Bryson during the Eurordis Symposium in Brussels (February 2016) about how the results from Advance-HTA relate to the new HTA programmes implemented for rare or ultra-rare conditions. We are grateful for his input and review of the paper. Conflict of Interest statement: KF has received fees from Sanofi, Genzyme and UCB for consulting in relation to rare diseases. KF has undertaken a range of other consultancy with other
more » ... ith other pharmaceutical companies but not related to rare diseases. EN has received fees from Contingo and Redmond Consulting, the latter not being related to rare diseases. No other conflicts of interest arise. Abstract Background Challenges commonly encountered in HTA of orphan medicinal products (OMPs) were identified in Advance-HTA. Since then, new initiatives have been developed to specifically address issues related to HTA of OMPs. Objective and Methods This study aimed to understand why these new HTA initiatives in England, Scotland and at European-level were established and whether they resolve the challenges of OMPs. The work of Advance-HTA was updated with a literature review and a conceptual framework of clinical, regulatory and economic challenges for OMPs was developed. The new HTA programmes were critiqued against the conceptual framework and outstanding challenges identified. Results The new programmes in England and Scotland recognise the challenges identified in demonstrating the value of ultra-OMPs (and OMPs) and that they require a different process to standard HTA approaches. Wider considerations of disease and treatment experiences from a multi-stakeholder standpoint are needed, combined with other measures to deal with uncertainty (e.g. managed entry agreements). While approaches to assessing this new view of value of OMPs, extending beyond cost/QALY frameworks, differ, their criteria are similar. These are complemented by a European initiative that fosters multi-stakeholder dialogue and consensus about value determinants throughout the life-cycle of an OMP. Conclusion New HTA programmes specific to OMPs have been developed but questions remain about whether they sufficiently capture value and manage uncertainty in clinical practice.
doi:10.1016/j.healthpol.2017.03.009 pmid:28400128 fatcat:hq42zoqnwjfz5f2ft7563yshhu